The effectiveness and tolerability of lercanidipine is independent of body mass index or body fat percent. The LERZAMIG study

British Journal of Cardiology

Volumn 13, Issue 6, 2006, Pages 434-440

  Barrios, Vicencio ^a   Escobar, Carlos ^a   Calderón, Alberto ^b   Navarro, Angel ^c   Ruilope, Luis M ^d  

^a HOSPITAL RAMÓN Y CAJAL   (Spain)

^b Primary Care Center Rosa de Luxemburgo   (Spain)

^c Recordati Spain   (Spain)

^d HOSPITAL UNIVERSITARIO 12 DE OCTUBRE   (Spain)

Author keywords

Body fat percent; Body mass index; Hypertension; Lercanidipine; Obesity

Indexed keywords

ANGIOTENSIN RECEPTOR ANTAGONIST; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM CHANNEL BLOCKING AGENT; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; LERCANIDIPINE;

ADULT; AGED; ANTIHYPERTENSIVE ACTIVITY; ARTICLE; ASTHENIA; BIOENERGY; BLOOD PRESSURE REGULATION; BODY FAT; BODY MASS; CLINICAL EFFECTIVENESS; CLINICAL TRIAL; DIASTOLIC BLOOD PRESSURE; DISEASE SEVERITY; DIZZINESS; DRUG DOSE TITRATION; DRUG EFFICACY; DRUG ERUPTION; DRUG INDUCED HEADACHE; DRUG RESPONSE; DRUG TOLERABILITY; DRUG WITHDRAWAL; ESSENTIAL HYPERTENSION; FEMALE; FLUSHING; FOLLOW UP; FOOT EDEMA; HEART PALPITATION; HUMAN; IMPEDANCE; LOW CALORY DIET; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; OBESITY; OPEN STUDY; PATIENT COMPLIANCE; PRIMARY MEDICAL CARE; RASH; SIDE EFFECT; SYSTOLIC BLOOD PRESSURE;

EID: 33846062554     PISSN: 09696113     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (39)

1. McClellan KJ, Jarvis B. Lercanidipine: a review of its use in hypertension. Drugs 2002;60: 1123-40.
2. Epstein M. Lercanidipine: a novel dihydropyridine calcium-channel blocker. Heart Dis 2001;3:398-407.
3. Herbette LG, Vecchiarelli M, Sartani A, Leonardi A. Lercanidipine: short plasma half-life, long duration of action and high cholesterol tolerance. Updated molecular model to rationalize its pharmacokinetic properties. Blood Press 1998;2(suppl):10-17.
4. Meredith PA. Lercadinidipine: a novel lipophilic dihydropyridine calcium antagonist with long duration of action and high vascular selectivity. Exp Opin Invest Drugs 1999;8: 1043-62.
5. Guarneri L, Angelico P, Ibba M et al. Pharmacological in vitro studies of the new 1,4-dihydropyridine calcium antagonist lercanidipine. Arzneimittelforschung 1996;46: 15-24.
6. Soma MR, Natali M, Donetti E et al. Effect of lercanidipine and its (R)-enantiomer on atherosclerotic lesions induced in hypercholesterolemic rabbits. Br J Pharmacol 1998;125: 1471-6.
7. Martinez ML, Lopes LF, Coelho EB et al. Lercanidipine reduces matrix metalloproteinase-9 activity in patients with hypertension. J Cardiovasc Pharmacol 2006;47:117-22.
8. Angelico P, Guarneri L, Leonardi A, Testa R. Vascular-selective effect of lercanidipine and other 1,4-dihydropyridines in isolated rabbit tissues. J Pharm Pharmacol 1999;51:709-14.
9. Poncelet P, Ribstein J, Goullard L, Bassous M, Gres CS, Clerson P. Efficacy and acceptability of lercanidipine are not age dependent in patients with essential hypertension: the AGATE study. [Article in French]. Ann Cardiol Angeiol (Paris) 2004;53:123-30.
10. Barrios V, Navarro A, Esteras A et al. Antihypertensive efficacy and tolerability of lercanidipine in daily clinical practice. The ELYPSE Study. Blood Press 2002;11:95-100.
11. Omboni S, Zanchetti A. Antihypertensive efficacy of lercanidipine at 2.5, 5 and 10 mg in mild to moderate essential hypertensives assessed by clinic and ambulatory blood pressure measurements. Multicenter Study Investigators. J Hypertens 1998;16:1831-8.
12. Leonetti G, Magnani B, Pessina AC, Rappelli A, Trimarco B, Zanchetti A; COHORT Study Group. Tolerability of long-term treatment with lercanidipine versus amlodipine and lacidipine in elderly hypertensives. Am J Hypertens 2002;15:932-40.
13. Cherubini A, Fabris F, Ferrari E et al. Comparative effects of lercanidipine, lacidipine, and nifedipine gastrointestinal therapeutic system on blood pressure and heart rate in elderly hypertensive patients: the Elderly and LErcanidipine (ELLE) study. Arch Gerontol Geriatr 2003;37:203-12.
14. Romito R, Pansini MI, Perticone F, Antonelli G, Pitzalis M, Rizzon P. Comparative effect of lercanidipine, felodipine, and nifedipine GITS on blood pressure and heart rate in patients with mild to moderate arterial hypertension: the Lercanidipine in Adults (LEAD) Study. J Clin Hypertens (Greenwich) 2003;5:249-53.
15. James IG, Jones A, Davies P. A randomised, double-blind, double-dummy comparison of the efficacy and tolerability of lercanidipine tablets and losartan tablets in patients with mild to moderate essential hypertension. J Hum Hypertens 2002;16:605-10.
16. Bang LM, Chapman TM, Goa KL. Lercanidipine. A review of its efficacy in the management of hypertension. Drugs 2003; 63:2449-72.
17. Morse SA, Bravo PE, Morse MC, Reisin E. The heart in obesity-hypertension. Expert Rev Cardiovasc Ther 2005;3:647-58.
18. Hall JE. The kidney, hypertension, and obesity. Hypertension 2003;41:625-33.
19. El-Atat F, Aneja A, Mcfarlane S, Sowers J. Obesity and hypertension. Endocrinol Metab Clin North Am 2003;32:823-54.
20. Hall JE, Jones DW, Kuo JJ, da Silva A, Tallam LS, Liu J. Impact of the obesity epidemic on hypertension and renal disease. Curr Hypertens Rep 2003;5:386-92.
21. Lamounier-Zepter V, Bornstein SR, Ehrhart-Bornstein M. Mechanisms of obesity-related hypertension. Horm Metab Res 2004;36: 376-80.
22. Correia ML, Haynes WG. Obesity-related hypertension: is there a role for selective leptin resistance? Curr Hypertens Rep 2004;6: 230-5.
23. Pischon T, Sharma AM. Recent developments in the treatment of obesity-related hypertension. Curr Opin Nephrol Hypertens 2002;11: 497-502.
24. Pischon T, Sharma AM. Use of beta-blockers in obesity hypertension: potential role of weight gain. Obes Rev 2001;2:275-80.
25. Gus M, Fuchs SC, Moreira LB et al. Association between different measurements of obesity and the incidence of hypertension. Am J Hypertens 2004;17:50-3.
26. Chobanian AV, Bakris GL, Black H et al. The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. The JNC 7 report. JAMA 2003;289: 2560-72.
27. 2003 European Society of Hypertension-European Society of Cardiology guidelines for management of arterial hypertension. J Hypertens 2003;21:1011-53.
28. Gasser R, Köppel H, Klein W. Lercanidipine, a new third generation Ca-antagonist in the treatment of hypertension. J Clin Basic Cardiol 1999;2:169-74.
29. Lee SH, Kim YS, Sunwoo S, Huh BY. A retrospective cohort study on obesity and hypertension risk among Korean adults. J Korean Med Sci 2005;20:188-95.
30. Nakanishi N, Nakamura K, Ichikawa S, Suzuki K, Kawashimo H, Tatara K. Risk factors for the development of hypertension: a 6-year longitudinal study of middle-aged Japanese men. J Hypertens 1998;16:753-9.
31. Yarnell JW, Patterson CC, Thomas HF, Sweetnam PM. Comparison of weight in middle age, weight at 18 years, and weight change between, in predicting subsequent 14 year mortality and coronary events: Caerphilly Prospective Study. J Epidemiol Community Health 2000;54:344-8.
32. Abellán J, Leal M, Hernández-Menárguez F et al. Efficacy of moxonidine in the treatment of hypertension in obese, noncontrolled hypertensive patients. Kidney Int 2005;67(suppl): S20-S24.
33. Rocchini AP. Cardiovascular regulation in obesity-induced hypertension. Hypertension 1992;19:156-60.
34. Hall JE, Brands MW, Henegar JR. Mechanisms of hypertension and kidney disease in obesity. Ann N Y Acad Sci 1999;892:91-107.
35. Grassi G, Cattaneo BM, Seravalle G, Colombo M, Cavagnini F, Mancia G. Obesity and the sympathetic nervous system. Blood Press 1996;1(suppl):43-6.
36. Sharma AM, Pischon T, Engeli S, Scholze J. Choice of drug treatment for obesity-related hypertension: where is the evidence? J Hypertens 2001;19:667-74.
37. Barrios V, Tomas JP, Navarro A et al. Effectiveness and tolerability of lercanidipine in diabetic, isolated systolic hypertensive, and elderly patients. Subgroups analysis of the ELYPSE study. Hipertensión 2003;20:347-53.
38. Barrios V, Honorato J, Llisterri JL, Calderon A, Navarro A, de la Figuera M. Comparative tolerability of lercanidipine with other calcium channel blockers: the TOLERANCE study. J Clin Hypertens 2006;8(suppl A):A74.
39. Ram CV. Usefulness of lercanidipine, a new calcium antagonist, for systemic hypertension. Am J Cardiol 2002;89:24-5.